

MAINE STATE LEGISLATURE

The following document is provided by the
LAW AND LEGISLATIVE DIGITAL LIBRARY
at the Maine State Law and Legislative Reference Library
<http://legislature.maine.gov/lawlib>



Reproduced from electronic originals
(may include minor formatting differences from printed original)

STATE OF MAINE
130TH LEGISLATURE
SECOND REGULAR SESSION



Disposition of bills and summaries of all laws enacted or finally passed

**JOINT STANDING COMMITTEE ON HEALTH AND
HUMAN SERVICES**

July 2022

STAFF:

ANNA BROOME, SR. LEGISLATIVE ANALYST
SAMUEL SENFT, LEGISLATIVE ANALYST
OFFICE OF POLICY AND LEGAL ANALYSIS
13 STATE HOUSE STATION
AUGUSTA, ME 04333
(207) 287-1670
<http://legislature.maine.gov/opla/>

MEMBERS:

SEN. NED CLAXTON, CHAIR
SEN. JOSEPH BALDACCI
SEN. MARIANNE MOORE

REP. MICHELE MEYER, CHAIR
REP. MARGARET CRAVEN
REP. ANNE C. PERRY
REP. COLLEEN M. MADIGAN
REP. HOLLY B. STOVER
REP. SAMUEL LEWIS ZAGER
REP. KATHY IRENE JAVNER
REP. ABIGAIL W. GRIFFIN
REP. JONATHAN M. CONNOR
REP. MICHAEL H. LEMELIN

JOINT STANDING COMMITTEE ON HEALTH AND HUMAN SERVICES

LD 1722 An Act To Ensure Access to All Paths to Recovery for Persons Affected by Opioids Using Money Obtained through Litigation against Opioid Manufacturers

ENACTED LAW SUMMARY

Public Law 2021, chapter 661 provides that funds received from opioid litigation may be deposited into the account described by a memorandum of understanding between the Attorney General's office and local stakeholders to receive funding from recently settled litigation. The memorandum establishes the terms under which these funds may be spent. The law establishes the Maine Recovery Council to direct fund disbursement and requires the Attorney General, by February 1st of each year, to submit a report to the joint standing committee of the Legislature having jurisdiction over health and human services matters describing the activities of the council and the status of the Maine Recovery Fund and listing information on fund disbursements and information related to the outcomes of funded activities.

Public Law 2021, chapter 661 was enacted as an emergency measure effective April 25, 2022.

LD 1729 Resolve, To Assess the Feasibility of the Production of Insulin and Insulin Analogs in Maine

ENACTED LAW SUMMARY

Resolve 2021, chapter 166 requires the Department of Health and Human Services to convene a commission consisting of representatives of other government agencies or entities and interested groups to assess the feasibility of having the University of Maine System and other appropriate institutions or a public-private partnership between the University of Maine System, other appropriate institutions and a licensed drug manufacturer produce insulin in the State and provide such insulin at reduced, low or no cost to low-income residents of the State. The resolve requires the commission to assess the feasibility of such a program by reviewing factors including potential savings and additional costs to the University of Maine System and the State, the number of individuals who would benefit from such a program, potential regulatory or legal obstacles, available alternatives to providing insulin to low-income individuals at low or no cost and to seek input from members of the Legislature when making its assessment. It also requires that the commission explore options for capping copayments for insulin and insulin analogs provided through private insurers, the potential for the State to engage in volume purchasing of insulin and insulin analogs at reduced cost, the mechanisms by which the State could establish a program to distribute insulin and insulin analogs to residents of the State, opportunities to establish an interstate compact with other New England states to reduce insulin and insulin analog costs in compact states, opportunities to establish a public entity to manage the purchasing and distribution of insulin and insulin analogs with the possibility of eventual transition to a private entity, opportunities to establish a model facility to affordably manufacture insulin and insulin analogs and to distribute insulin and insulin analogs to Maine residents, and opportunities to procure dedicated funding to support the manufacture of insulin and insulin analogs and the distribution of insulin and insulin analogs to Maine residents. The resolve requires the commission to provide a